ArticleFrontiers in cell and developmental biology2021
Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- A m6A/m1A/m5C-related eight-gene signature predicts prognosis and correlates with immune microenvironment in pediatric acute myeloid leukemia.Translational pediatrics · 2026Article
- Recognition of immunogenomic signature and prognostic value of the subtype of epithelial-mesenchymal transition in breast cancer.Biochemistry and biophysics reports · 2026Article
- RNA mDiscover oncology · 2025Article
- New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy.Frontiers in immunology · 2025Review
- Construction and validation of a prognostic signature based on microvascular invasion and immune-related genes in hepatocellular carcinoma.Scientific reports · 2024Article
- RNA modifications in the progression of liver diseases: from fatty liver to cancer.Science China. Life sciences · 2024Review
- Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification.Cancer gene therapy · 2024Review
- Article
- Landscape of mFrontiers in pharmacology · 2024Review
- A novel molecular classification system based on the molecular feature score identifies patients sensitive to immune therapy and target therapy.Frontiers in immunology · 2024Article
- Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.BMC cancer · 2022Article
- Developing an Immune-Related Signature for Predicting Survival Rate and the Response to Immune Checkpoint Inhibitors in Patients With Glioma.Frontiers in genetics · 2022Article
- The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma.Frontiers in immunology · 2022Review
- Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.Frontiers in immunology · 2022Article
- The Detection and Verification of Two Heterogeneous Subgroups and a Risk Model Based on Ferroptosis-Related Genes in Hepatocellular Carcinoma.Journal of oncology · 2022Article
- Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.